BCL2 and B-cell chronic lymphocytic leukemia: Genetic mutations responsible for resistance to venetoclax were recently detected in patients with progressive Chronic Lymphocytic Leukemia (CLL) with G101V, F104C, F104L, and D103Y mutations in the BCL-2 gene.